推薦產(chǎn)品
3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole 2-(chloromethyl)-3-methylpyridinehydrochloride 1-(2-bromo-4-methylphenyl)ethanone 3-chloroisoquinoline-4-carbonitrile 5,8-dichloropyrido[3,2-d]pyridazine 2-bromomalononitrile 2-(4-(bromomethyl)phenyl)benzo[d]thiazole 1-(bromomethyl)-3-methoxy-2-nitrobenzene 6-bromo-1H-[1,2,3]triazolo[4,5-b]pyridine 4-iodo-2-((trimethylsilyloxy)methyl)thiazole 6-iodoimidazo[1,2-a]pyridine-3-carbonitrile 2-(4-chlorophenyl)-2-morpholinoacetonitrile 4-chloro-7H-pyrrolo[2,3-d]pyrimidine 4-chloroisothiazole 5-bromo-6-chloro-1H-indole 7-chloro-3H-imidazo[4,5-b]pyridine ethyl3-(4-formylphenyl)propanoate 2,3-dibromobenzaldehyde 1-(5H-chromeno[2,3-b]pyridin-7-yl)ethanone 5H-chromeno[2,3-b]pyridin-5-one 3-chloroisoquinoline-4-carbaldehyde (E)-2-(3-oxoprop-1-enyl)benzaldehyde methyl4-formyl-3-nitrobenzoate 5,6-dimethoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-one 1-methylbicyclo[4.1.0]heptan-3-one 3-nitro-4-(trifluoromethoxy)benzaldehyde 2-hydroxyquinoline-6-carbaldehyde 2-nitro-3-(trifluoromethyl)benzaldehyde 1-(2-fluoro-4-methoxyphenyl)propan-2-one tert-butyl3-fluoro-4-oxopiperidine-1-carboxylate tert-butyl3-oxopropylcarbamate 2,2-dimethylcyclohexanone 9H-carbazole-3-carbaldehyde N,N-dimethyl-2-oxoacetamide 2-methylpent-4-yn-2-ol 3-tert-butyl-4-hydroxybenzonitrile 4-bromo-2-tert-butylphenol 1,3-dibutoxypropan-2-ol methyl4-hydroxyquinoline-6-carboxylate methyl3-cyano-4-hydroxybenzoate 4-chloro-6-methoxyquinolin-7-ol 3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol 2-(2-aminothiazol-5-yl)ethanolhydrochloride (R)-ethyl2-chloropropanoate (S)-4-amino-5-(4,4-dimethylcyclohexylamino)-5-oxopentanoicacid (1s,4s)-4-hydroxycyclohexanecarboxylicacid (S)-2-(tetrahydrofuran-3-yloxy)aceticacid (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol (R)-4-(hydroxymethyl)oxazolidin-2-one (S)-4-(hydroxymethyl)oxazolidin-2-one 化工資訊 國家衛(wèi)生和計(jì)劃生育委員會(huì)副主任、國家中醫(yī)藥管理局局長王國強(qiáng)6月1日稱，中醫(yī)藥標(biāo)準(zhǔn)化工作是“潮流所向、大勢所趨”。
王國強(qiáng)是在當(dāng)日召開的國際標(biāo)準(zhǔn)化組織/中醫(yī)藥技術(shù)委員會(huì)（簡稱ISO/TC249）第六次全體會(huì)議上作出上述表態(tài)的。此次會(huì)議是中國自2010年承辦ISO/TC249第一次全體會(huì)議以來，再次爭取到會(huì)議承辦權(quán)，被認(rèn)為是ISO/TC249對中方工作實(shí)績的肯定。
隨著中醫(yī)藥在全球的廣泛傳播與應(yīng)用，中醫(yī)藥國際標(biāo)準(zhǔn)的需求日益突顯。2009年，ISO/TC249正式成立，旨在建立中醫(yī)藥標(biāo)準(zhǔn)化新格局。至此，在全球最大、最權(quán)威的國際標(biāo)準(zhǔn)組織有了為中醫(yī)藥量身打造的國際標(biāo)準(zhǔn)研制平臺(tái)。
5年來，中國已從中醫(yī)藥國際標(biāo)準(zhǔn)化領(lǐng)域的初學(xué)者，成長為率先發(fā)布ISO中醫(yī)藥國際標(biāo)準(zhǔn)，擁有ISO中醫(yī)藥標(biāo)準(zhǔn)項(xiàng)目提案數(shù)量最多，專家人數(shù)最多的中醫(yī)藥標(biāo)準(zhǔn)制定的引領(lǐng)者，進(jìn)一步擴(kuò)大了中醫(yī)藥在世界的影響力，展示了中醫(yī)藥幾千年來打下的堅(jiān)實(shí)理論基礎(chǔ)，以及服務(wù)世界人民健康的能力。
